Read More Pharma Industry News Neuphoria Therapeutics shares jumped while Scancell plunged, and the merger terms explain why Scancell’s Neuphoria Therapeutics merger unlocks Nasdaq access and up to $89 million, but dilution and debt reshape the iSCIB1+ outlook. bySoujanya RaviJuly 27, 2026